Literature DB >> 16750735

Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery.

Emad Al-Shawaf1, Adel Ayed, Ivan Vislocky, Bosko Radomir, Najat Dehrab, Riad Tarazi.   

Abstract

OBJECTIVES: The purpose of this study was to compare the hemodynamic profiles and the postoperative insulin requirements in 2 groups of type 2 diabetic patients with depressed myocardial function who underwent elective surgery for coronary artery disease and who received levosimendan or milrinone for postcardiopulmonary bypass low-output syndrome.
DESIGN: Randomized controlled trial.
SETTING: The Chest Diseases Hospital, Safat, Kuwait. PARTICIPANTS: Type 2 diabetic patients undergoing elective surgery for coronary artery disease.
INTERVENTIONS: Fourteen patients and 16 patients received levosimendan and milrinone infusions, respectively, for treatment of the low-output syndrome.
MEASUREMENTS AND MAIN RESULTS: The hemodynamic, mixed venous oxygen saturation, oxygen extraction ratios, arterial lactate concentrations, and postoperative insulin infusion rates were serially documented for the first 48 hours after the diagnosis. The cardiac index and mixed venous oxygen saturation were significantly higher in the levosimendan group. The pulmonary capillary wedge pressure, systemic vascular resistance, and oxygen extraction ratios were significantly higher in the milrinone treatment group. The insulin requirements were similar for both of the treatment groups.
CONCLUSIONS: Levosimendan was more efficient than milrinone for treating the hemodynamic manifestations of the postcardiopulmonary bypass low-output syndrome. However, all the values in the milrinone treatment group were normalized. In this small population, both treatment groups had similar postoperative insulin requirements.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750735     DOI: 10.1053/j.jvca.2006.02.012

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  21 in total

Review 1.  Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.

Authors:  Geert Koster; Jørn Wetterslev; Christian Gluud; Jan G Zijlstra; Thomas W L Scheeren; Iwan C C van der Horst; Frederik Keus
Journal:  Intensive Care Med       Date:  2014-12-18       Impact factor: 17.440

2.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.

Authors:  Wanyu Wang; Xiaoshuang Zhou; Xinyang Liao; Bin Liu; Hai Yu
Journal:  J Anesth       Date:  2019-04-25       Impact factor: 2.078

Review 3.  Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.

Authors:  Alexandre Mebazaa; Antonis A Pitsis; Alain Rudiger; Wolfgang Toller; Dan Longrois; Sven-Erik Ricksten; Ilona Bobek; Stefan De Hert; Georg Wieselthaler; Uwe Schirmer; Ludwig K von Segesser; Michael Sander; Don Poldermans; Marco Ranucci; Peter C J Karpati; Patrick Wouters; Manfred Seeberger; Edith R Schmid; Walter Weder; Ferenc Follath
Journal:  Crit Care       Date:  2010-04-28       Impact factor: 9.097

Review 4.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Julia Schumann; Eva C Henrich; Hellen Strobl; Roland Prondzinsky; Sophie Weiche; Holger Thiele; Karl Werdan; Stefan Frantz; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

5.  Garlic Oil Alleviates MAPKs- and IL-6-mediated Diabetes-related Cardiac Hypertrophy in STZ-induced DM Rats.

Authors:  Sheng-Huang Chang; Chung-Jung Liu; Chia-Hua Kuo; Hong Chen; Wen-Yuan Lin; Kun-Yu Teng; Sheng-Wei Chang; Chang-Hai Tsai; Fuu-Jen Tsai; Chih-Yang Huang; Bor-Show Tzang; Wei-Wen Kuo
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-15       Impact factor: 2.629

6.  Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials.

Authors:  Ritesh Maharaj; Victoria Metaxa
Journal:  Crit Care       Date:  2011-06-08       Impact factor: 9.097

7.  Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Authors:  Tiziana Bove; Andrea Matteazzi; Alessandro Belletti; Gianluca Paternoster; Omar Saleh; Daiana Taddeo; Roberto Dossi; Teresa Greco; Nikola Bradic; Ino Husedzinovic; Caetano Nigro Neto; Vladimir V Lomivorotov; Maria Grazia Calabrò
Journal:  Heart Lung Vessel       Date:  2015

8.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Konstantin Uhlig; Ljupcho Efremov; Jörn Tongers; Stefan Frantz; Rafael Mikolajczyk; Daniel Sedding; Julia Schumann
Journal:  Cochrane Database Syst Rev       Date:  2020-11-05

Review 9.  Levosimendan in critical illness: a literature review.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Federico Franchi; Luigi Muzzi; Menelaos Karanikolas; Sabino Scolletta
Journal:  J Clin Med Res       Date:  2014-02-06

Review 10.  Renal effects of levosimendan: a consensus report.

Authors:  Mehmet B Yilmaz; Elena Grossini; José C Silva Cardoso; István Édes; Francesco Fedele; Piero Pollesello; Matti Kivikko; Veli-Pekka Harjola; Julia Hasslacher; Alexandre Mebazaa; Andrea Morelli; Jos le Noble; Anders Oldner; Ignacio Oulego Erroz; John T Parissis; Alexander Parkhomenko; Gerhard Poelzl; Sebastian Rehberg; Sven-Erik Ricksten; Luís M Rodríguez Fernández; Markku Salmenperä; Mervyn Singer; Sascha Treskatsch; Bojan Vrtovec; Gerhard Wikström
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.